Table 3.
Cyclophosphamide metabolite formation following doses 1 and 5 of treatment in study patients alive with no disease as compared to relapsed patients.
| Dose 1 AUC0–6h (μg/ml.min) |
Dose 5 AUC0–6h (μg/ml.min) |
||||||
|---|---|---|---|---|---|---|---|
| CXCP | DCCP | KetoCP | CXCP | DCCP | KetoCP | ||
| All patients (n = 49) | Mean | 103.7 | 76.7 | 63.6 | 198.9 | 105.6 | 153.4 |
| SD | 60.9 | 49.6 | 27.5 | 137.9 | 60.9 | 61.3 | |
| Range | 35.4–352 | 21.4–285 | 19.9–141 | 90.6–921 | 37.5–287 | 69.8–353 | |
| Alive no disease (n = 38) | Mean | 103.9 | 70.1a | 62.2 | 199.0 | 100.4 | 148.1 |
| SD | 63.2 | 37.6 | 26.4 | 144.4 | 55.6 | 58.9 | |
| Relapsed (n = 9) | Mean | 102.4 | 122.0a | 71.5 | 198.1 | 138.7 | 182.5 |
| SD | 47.1 | 92.2 | 34.5 | 97.5 | 86.8 | 70.9 | |
CXCP – carboxyphosphamide; DCCP – dechloroethylcyclophosphamide; KetoCP – ketocyclophosphamide; SD – standard deviation; AUC – area under the plasma concentration-time curve.
a
DCCP AUC0–6h determined following dose 1 had a negative prognostic effect on progression free survival (p = 0.05).